Skip to main content

Table 2 Clinical variables affecting TDM implementation of vancomycin

From: Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database

Characteristic

Univariate analysis

Multivariate analysis

OR

95% CI

P value

OR

95% CI

P value

Age (years)

1.005

1.001–1.009

0.024 *

1.006

1.001–1.011

0.017 *

Sex (male)

1.290

1.049–1.586

0.016 *

1.221

0.984–1.515

0.069

Duration of vancomycin treatment (days)

1.056

1.038–1.074

<  0.001 *

1.059

1.041–1.078

<  0.001 *

Number of hospital beds

  ≤ 199 beds

0.358

0.245–0.524

<  0.001 *

0.299

0.197–0.452

<  0.001 *

 200–499 beds

1.103

0.875–1.390

0.408

1.079

0.831–1.399

0.569

  ≥ 500 beds

1.269

1.028–1.567

0.027 *

Clinical departments of prescription of vancomycin

 Internal Medicine

1.099

0.899–1.343

0.357

1.162

0.917–1.472

0.214

 Respiratory Medicine

1.436

0.937–2.200

0.097

1.473

0.925–2.344

0.103

 Pediatrics

0.513

0.302–0.871

0.013 *

0.680

0.365–1.267

0.224

 Other internal medicine

2.568

1.287–5.126

0.007 *

2.854

1.385–5.881

0.004 *

 Cardiology

0.697

0.258–1.881

0.476

1.090

0.379–3.133

0.873

 Other departments

0.812

0.653–1.011

0.062

Ward pharmacy service

1.477

1.210–1.803

<  0.001 *

1.514

1.232–1.861

<  0.001 *

  1. TDM Therapeutic Drug Monitoring, OR odds ratio, 95% CI: 95% confidence interval. *P-values ≤0.05 were considered statistically significant. The odds ratios of “number of hospital beds ≥500 beds” and “clinical departments of other departments” were not calculated because they had linear dependence with other factors